Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Aurélien Lambert

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9990-1201; OpenAlex author ID A5079681769. Sources: OpenAlex.

Their work

Papers
28 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 5 papers · 2023: 1 paper · 2024: 5 papers · 2025: 3 papers · 2026: 8 papers

Papers 28

  1. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Co-author DOI 10.1016/j.ejca.2026.116227↗
  2. Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies. Co-author DOI 10.1016/j.ijrobp.2025.09.013↗
  3. Radiotherapy in the management of PDAC, from past to present. Co-author DOI 10.1016/j.tranon.2025.102632↗
  4. Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG … Co-author DOI 10.1097/sla.0000000000006449↗
  5. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. Co-author DOI 10.1200/jco-25-02508↗
  6. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  7. AI-Driven Patient Screening for Clinical Trials in Pancreatic Cancer: The PANCR-AI Pilot Retrospective Comparative Study. Last author DOI 10.2196/80268↗
  8. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  9. AI-based CT assessment of sarcopenia in borderline resectable pancreatic Cancer: A narrative review of clinical and technical perspectives. First author DOI 10.1016/j.compbiomed.2025.110659↗
  10. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  11. [Living with… pancreatic cancer]. Last author PMID 40476436↗
  12. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  13. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  14. DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib. Co-author DOI 10.1038/s41420-024-02188-9↗
  15. Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CC… Co-author DOI 10.1200/jco.22.02668↗
  16. Role of molecular biology in the management of pancreatic cancer. Co-author DOI 10.4251/wjgo.v16.i7.2902↗
  17. Adjuvant and neoadjuvant approaches in pancreatic cancer. First author DOI 10.1097/cco.0000000000000962↗
  18. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  19. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  20. DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy. Co-author DOI 10.3389/fonc.2022.1052163↗
  21. Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of t… Last author DOI 10.3390/cancers14163945↗
  22. Development of a Clinical-Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial. Last author DOI 10.3390/cancers14205068↗
  23. Future directions in drug development in pancreatic cancer. Co-author DOI 10.1053/j.seminoncol.2021.02.002↗
  24. Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13184724↗
  25. An update on treatment options for pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835919875568↗
  26. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Co-author DOI 10.1177/1756283x17713879↗
  27. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. Co-author DOI 10.1371/journal.pone.0183288↗
  28. Current standards and new innovative approaches for treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.12.026↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thierry Conroy · 15 shared papers, 2016–2026 · strength 2.64
  2. Alexandre Harlé · 9 shared papers, 2022–2026 · strength 1.91
  3. Michel Pierre Ducreux · 7 shared papers, 2016–2026 · strength 1.32
  4. Jerome F. Cros · 6 shared papers, 2024–2026 · strength 1.24
  5. James Biagi · 6 shared papers, 2022–2026 · strength 1.19
  6. Andréa Witz · 5 shared papers, 2022–2026 · strength 1.16
  7. Jean‐Baptiste Bachet · 6 shared papers, 2016–2026 · strength 1.02
  8. Pascal R. Hammel · 5 shared papers, 2024–2026 · strength 0.96
  9. Pauline Gilson · 4 shared papers, 2022–2026 · strength 0.93
  10. Julie Dardare · 4 shared papers, 2022–2026 · strength 0.93
  11. Emmanuel Mitry · 5 shared papers, 2024–2026 · strength 0.87
  12. Anthony Turpin · 5 shared papers, 2022–2026 · strength 0.85
  13. Rémy Nicolle · 4 shared papers, 2024–2026 · strength 0.74
  14. Daniel John Renouf · 4 shared papers, 2024–2026 · strength 0.74
  15. Nelson Dusetti · 4 shared papers, 2024–2026 · strength 0.74
  16. Juan Iovanna · 3 shared papers, 2024–2026 · strength 0.55
  17. Jean‐Luc Van Laethem · 4 shared papers, 2016–2025 · strength 0.52
  18. Vinciane Rebours · 3 shared papers, 2024–2026 · strength 0.51
  19. Anthony Tarabay · 2 shared papers, 2024–2026 · strength 0.44
  20. Cristina Smolenschi · 2 shared papers, 2024–2026 · strength 0.44
  21. Antoine Hollebecque · 2 shared papers, 2024–2026 · strength 0.44
  22. Alice Boilève · 2 shared papers, 2024–2026 · strength 0.44
  23. Jean‐Emmanuel Bibault · 1 shared paper, 2025 · strength 0.42
  24. William Gehin · 1 shared paper, 2025 · strength 0.42
  25. Sarah Baudry · 1 shared paper, 2025 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.